close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

53.01 +0.04 (+0.08%)
Streaming Delayed Price Updated: 2:22 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Metsera, Inc. - Common Stock

< Previous 1 2 3 Next >
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
Where Will Pfizer Be in 5 Years?
Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past. 
Via The Motley Fool
Topics Intellectual Property World Trade
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Down 50%, Should You Buy the Dip on Pfizer?
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows. 
Via The Motley Fool
Topics Intellectual Property
3 Reasons to Buy Pfizer Stock Now
After years of underperformance, the future is looking brighter for the drugmaker. 
Via The Motley Fool
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts
Via Stocktwits
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October
You don't need to be rich to put your money to work on Wall Street. 
Via The Motley Fool
Topics Intellectual Property
3 Things You Need to Know if You Buy Pfizer Today
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it. 
Via The Motley Fool
Topics Intellectual Property
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These stocks could see growth take off over the next few years. 
Via The Motley Fool
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025. 
Via Benzinga
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market. 
Via The Motley Fool
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
From Metsera, Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Right now, these dividend payers are top options for folks who like to set it and forget it. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. 
Via The Motley Fool
Topics Intellectual Property
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
The company continues to improve its pipeline. 
Via The Motley Fool
Pfizer is Locking in New Growth Through a New Acquisition
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet. 
Via MarketBeat
Topics Artificial Intelligence
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
The pharmaceutical giant is again plunging headfirst into weight-loss drug development. 
Via The Motley Fool
Topics Intellectual Property
2 Top Passive Income Stocks to Buy Now
These dividend stocks offer high yields and growth catalysts that could support payouts for decades. 
Via The Motley Fool
Topics Bonds Economy Lawsuit
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, GTLS, MURA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, ODP, SMLR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?
Pfizer's plan to enter the booming obesity market took an expensive new turn. 
Via The Motley Fool
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Top stock movements in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Nvidia, Metsera, Oracle, Apple, Compass: Stocks Making The Biggest Moves Today
Via Stocktwits
Why Pfizer Stock Just Popped
Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today